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Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammatory
status, joint destruction, disability, and pain. Methotrexate (MTX) has been confirmed to reduce disease activity and
delay or stabilize the development of bone erosions. However, major drawbacks are that patients show great
interindividual variability in response to MTX and the unpredictable occurrence of side effects. A strategy for
personalized MTX treatment to predict its efficacy and toxicity has not yet been determined.
To establish personalized MTX therapy in Japanese patients with rheumatoid arthritis, we performed a preliminary
study for predicting better methotrexate efficacy including single-nucleotide polymorphisms (SNPs) for MTX-related
transporters/enzymes.
Methods: Disease control status (good or poor) was judged by the number of Disease Activity Scores (DAS28) of
<2 for 6–12 months. The response index R was calculated by the improved area under the curve (AUC) of the
DAS28 score for 0–3 or 0–6 months by dividing the cumulative dose of MTX during 0–3 or 0–6 months,
respectively. Genotyping of alleles of RFC1 80G > A, RFC1 –43 T > C, FPGS 1994G > A, GGH 401C > T, MTHFR
1298A > C, and TYMS 3'-UTR (−6/+6) was performed using the real-time PCR system.
Results: Seven of 21 patients were judged as good responders in terms of disease control, and the remainder as
poor responders. For 0–3 months after starting MTX administration, the median cumulative dose and improved
DAS28 AUC in the good and poor response groups were 96.0 mg and 25.4 and 118.0 mg and 23.4, respectively. For
0–6 months, the median cumulative dose and improved DAS28 AUC in the good and poor response groups were
192.0 mg and 51.0 and 214.0 mg and 47.6, respectively. Statistically significant differences between the 2 groups in
the 0–6-month period were observed in DAS28 AUC improvement and index R. A slight tendency for a correlation
between G/G genotypes and A allele genotypes in RFC1 80 genotypes was observed, although it did not reach
statistical significance.
Conclusion: This study suggested that aggressive RA treatment with MTX from the early period of administration is
necessary to obtain a good response after 6 months, although no SNPs predicting a better treatment response to
MTX were identified.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by systemic inflammatory status, joint
destruction, disability, and pain [1, 2]. However, the
mechanism of RA onset is not fully clear. Currently,
clinical remission, that is, complete suppression of dis-
ease activity, is considered the major goal of RA treat-
ment [3–6], and a significant proportion of patients
receiving routine follow-up care can achieve this [7–9],
although long-term drug therapy is required. Among
agents for the treatment of RA, methotrexate (MTX) is
the anchor drug and the most widely used disease-
modifying antirheumatoid drug (DMARD). MTX has
been confirmed to reduce disease activity and delay or
stabilize the development of bone erosions [10, 11].
However, major drawbacks are that patients show
great interindividual variability in response to MTX,
only about 50 % show a good clinical response, and
the unpredictable occurrence of a broad spectrum of
side effects including alopecia, gastrointestinal dis-
turbances, elevation of liver enzyme levels, and bone
marrow suppression [12, 13] forces 30 % of patients
to discontinue therapy [14, 15].
In the body, MTX is transported intracellularly via
the reduced folate carrier 1 (RFC-1/SLC19A1). Inside
cells [16, 17], MTX adds up to 4 additional glutamate
moieties via folypolyglutamate synthetase (FPGS) [18–
20] and then forms MTX-polyglutamates (MTXPGs).
Subsequently, the terminal glutamate MTXPG mole-
cules are removed via gamma-glutamyl hydrolase
(GGH) [21–23] and returned to MTX (which is the
MTX monoglutamate form) and it is rapidly trans-
ported out of the cell by multidrug-resistant proteins.
The mechanism of action of MTX is as a folate an-
tagonist [24], and therefore intracellular MTXPGs
bind to dihydrofolate reductase (DHFR) and other fol-
ate pathway enzymes, thereby exerting antiinflamma-
tory effects, although the detailed mechanism of
action remains unclear.
Despite many efforts to identify factors predicting the
response to MTX treatment, which have focused on drug
disposition including single-nucleotide polymorphisms
(SNPs) in genes coding for folate pathway enzymes and
MTX transport into and out of cells in patients with RA
in relation to MTX efficacy and toxicity [25–32], a strat-
egy for personalized MTX treatment to predict its efficacy
and toxicity has not yet been determined.
The purpose of this study was to clarify the relation-
ship between treatment response to MTX and disease
control status, identify the genetic polymorphisms for
MTX-related transporters/enzymes, and obtain better
supportive information to devise a strategy for MTX
administration for personalized therapy in Japanese
patients with RA.
Methods
Participants, study design, and setting
This was a retrospective observational cohort study.
The patients included were unrelated Japanese with
RA who regularly visited the PS Clinic (Fukuoka,
Japan) from December 2010 to January 2011 and
had been administered MTX continuously for
6 months or more, and/or were administered MTX
for the first time. All patients gave written informed
consent for participation in this study after receiving
an explanation of the protocol and goals, especially
in order to determine the SNPs related to the MTX
treatment response from blood samples. The pa-
tients’ clinical data were retrospectively collected
from their medical records. Patients who were re-
ceiving the combination of low-dose corticosteroids
and nonsteroidal antiinflammatory drugs at the same
fixed dose during the study period were included.
Patients who received biologic agents were excluded
from the study.
The study protocol was approved by the Ethics
Committee of the LTA Clinical Pharmacology Center
and Faculty of Pharmacy, Keio University.
Study drug
The proprietary MTX brands used were Rheumatrex
2-mg capsules (Pfizer, Inc., Tokyo, Japan), Metolate 2-
mg tablets (Santen Pharmaceutical Co., Ltd., Osaka,
Japan), and Methotrexate 2-mg tablets (Mitsubishi
Tanabe Pharma, Tokyo, Japan). The dose of MTX was
determined by individual patients’ physicians based on
stable clinical symptoms. The MTX doses when dis-
continuation was required due to the appearance of
drug-related side effects were excluded from the
study analysis.
Patient characteristics
Gender, age at the commencement of MTX admin-
istration, C-reactive protein (CRP) level, erythrocyte
sedimentation rate (ESR), rheumatoid factor (RF)
level, Disease Activity Score 28-CRP (DAS28-CRP),
serum creatinine (Scr), duration of RA, and history of
DMARD administration were taken from patients’ med-
ical records.
Outcome measures
Evaluation of treatment response to MTX and disease
control
DAS28-CRP was used as the index of disease activ-
ity status. DAS28 was calculated from the following
formula with the number of tender joints from
among 28 joints (T28), number of swollen joints
(S28), Visual Analogue Scale (VAS) score, and CRP
level [33].
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Disease control was evaluated based on the value of
DAS28-CRP for 6–12 months after the commence-
ment of MTX administration (Fig.1). Good control
was defined as when a patient received a fixed dose
of MTX for 6–12 months after the start of adminis-
tration (i.e., no change in the MTX dose) and DAS28
scores of >2 were recorded less than once per month
on a day when a physician was visited. All other cases
were defined as poor disease control.
The cumulative dose of MTX at 3 and 6 months
after the start of MTX administration and the area
under the curve of the DAS28 score (DAS28-AUC)
were calculated using the trapezoidal rule for each
patient. To adjust for the difference in the MTX
treatment response due to the variation in patients’
DAS28 scores at the commencement of MTX admin-
istration, we assumed that a DAS28 score of 10 was
maintained for 3 and 6 months, and in each case the
total value of the DAS28 area was 30 during 0–3
months and 60 during 0–6 months, respectively. The
improved DAS28 area was calculated by deducting
each actual DAS28 area from the DAS28-AUC (30 in
3 months, 60 in 6 months). The value for the im-
proved DAS28 area was divided by the cumulative
dose of MTX, that is, we assumed that the improved
DAS28 area per milligram of MTX was the index R
of treatment response. The results in the good re-
sponse group were then compared with those in the
poor response group. That is, R = improved DAS28
area after the commencement of MTX administration
during a 3-month or 6-month period/cumulative dose
of MTX during the 3-month or 6-month period.
The evaluation periods for the index R of treatment
response were 0–3 months and 0–6 months after the
commencement of MTX administration.
Pharmacodynamic factors
As SNPs related to the MTX treatment response, RFC1
80G> A, FPGS 1994G> A, GGH –401C> T, methy-
lenetetrahydrofolate reductase (MTHFR) 1298A > C,
and thymidylate synthase (TYMS) 3′-UTR (+6/–6)
were evaluated in all patients. The index R of treat-
ment response was compared between the RFC1
80 G/G genotype and A allele, FPGS 1994G allele
and A/A genotype, GGH −401 C/C genotype and T
allele, MTHFR 1298A allele and C/C genotype, and
TYMS 3′-UTR −6/–6 genotype and +6 allele.
Genotyping method
DNA extraction For genetic analysis, 5 ml of peripheral
blood was collected from each patient using the standard
venipuncture technique in tubes containing ethylenedi-
aminetetraacetic disodium salt and stored at −20 °C until
DNA extraction. DNA was extracted using the Wizard
Genomic DNA Purification Kit (Promega Corporation,
Madison, WI, USA). DNA extraction procedures were
performed following the manufacturer’s instructions.
Total genomic DNA was quantified and its purity and in-
tegrity were analyzed using the GE Healthcare GeneQuan
1300 Spectrophotometer (Fisher Scientific, Pittsburgh, PA,
USA).
Genotyping of alleles of the RFC1 80G> A, RFC1 –
43 T > C, FPGS 1994G> A, GGH 401C> T, MTHFR
1298A> C, and TYMS 3′-UTR (−6/+6) Genotyping of
alleles of RFC1 80G >A (rs1051266), RFC1 –43 T >C
(rs1131596), FPGS 1994G >A (rs10106), GGH 401C >T
(rs3758149), MTHFR 1298A >C (rs1801131), and TYMS
3′-UTR (−6/+6) (rs16430) was performed using the Taq-
Man SNP Genotyping Assay from Applied Biosystems
(Foster City, CA, USA) with fluorogenic binding probes.
PCR amplification with the real-time PCR method was per-
formed in 25 μL of reaction mixture including genomic
DNA 20 ng (60 ng for FPGS 1994G >A), 0.63 μL of 40 ×
TaqMan SNP Genotyping Assay Mix (0.32 μL in RFC1
80G >A), and TaqMan Universal PCR Master Mix 12.5 μL.
The reaction conditions of PCR were as follows: initial de-
naturation for 10 min at 95 °C; 40 cycles at 92 °C/15 s; and
annealing and extension for 1 min at 60 °C (55 °C for FPGS
1994G >A). The PCR system used was the StepOnePlus
real time PCR system (Applied Biosystems).
Statistical analysis
Comparisons between cumulative doses of MTX, im-
proved DAS28 areas, index R, and disease control status
were performed using the Mann-Whitney U-test. For
comparisons between index R for 0–6 months after
the start of MTX administration and RFC1, FPGS,
GGH, MTHFR, and TYMS genotypes, the Mann-
Whitney U-test was performed. p Values of less than
Fig. 1 Figure Relationship between improved DAS28 area and
evaluation periods of disease control status after the start of MTX
administration. DAS28: Disease Activity Score-28 joints
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0.05 were considered to represent statistically signifi-
cant differences. All analyses were conducted using
PASW Statistics 18 (SPSS Inc., Chicago, IL, USA).
Results
Study participants
A total of 21 RA patients (3 men, 18 women) were
included in this study. Patient characteristics at the
start of MTX administration are shown in Table 1.
All patients were taking folic acid, but there was no
concomitant use of DMARDs. Seven of 21 patients
were judged as showing a good response, and the
remaining 14 patients as showing a poor response.
Comparisons between cumulative dose of MTX, improved
DAS28 area, index R, and disease control status
Table 2 shows comparisons between disease control status
for 6–12 months and cumulative dose of MTX, improved
DAS28 area, and index R for 0–3 months and 0–6 months
after the commencement of MTX administration between
the good control and poor control groups. For 0–3
months after starting MTX administration, the cumulative
dose of MTX (median [25–75th percentile]) was 96.0
(94.0–116.0) mg in the good control group (n = 7)
and 118.0 (100.0–124.0) mg in the poor control
group (n = 14). The difference between the 2 groups
was not statistically significant (p = 0.322). The im-
proved DAS28 area was 25.4 (24.5–26.1) in the good
control group (n = 7) and 23.4 (22.6–24.5) in the
poor control group (n = 14). It was therefore signifi-
cantly greater in the good control group (p = 0.004).
Index R was 0.25 (0.22–0.27) in the good control
group and 0.20 (0.19–0.24) in the poor control
group. A tendency for a greater index R value was
thus observed in the good control group (p = 0.079).
For 0–6 months after starting MTX administration,
the cumulative dose of MTX (median [25–75th per-
centile]) was 192.0 (166.0–212.0) mg in the good
control group (n = 7) and 214.0 (196.0–220.0) mg in
the poor control group (n = 14) (p = 0.287). The im-
proved DAS28 area was 51.0 (49.7–52.2) in the good
(n = 7) and 47.6 (45.1–48.4) in the poor control group
(n = 14), meaning that the improvement was signifi-
cantly greater in the former (p = 0.001). Index R was
0.26 (0.24–0.30) and 0.22 (0.21–0.24) in the good and
poor control group, respectively (p = 0.025).
Comparisons between index R for 0–6 months and RFC1,
FPGS1994, GGH452, MTHFR1298, and TYMS 3′-UTR
genotypes
Table 3 shows comparisons between index R for 0–6
months after the commencement of MTX administra-
tion and RFC1, FPGS1994, GGH452, MTHFR1298,
and TYMS 3′-UTR genotypes. There were no statisti-
cally significant differences among them, although a
slight tendency for a correlation between G/G geno-
types and A allele genotypes in RFC1 80 genotypes
was observed (p = 0.112).
Table 1 Patient clinical characteristics at the start of MTX
administration
No. of patients 21
Women, % 85.7
Age (years) 57 (33–69)
DAS28-CRP 4.00 (2.31–6.66)
CRP (mg/dL) 1.26 (0.07–11.53)
ESR (mm/h) 30 (11–95)
RF (IU/mL) 85 (3–260)
Scr (mg/dL) 0.60 (0.45–1.02)
Duration of RA (months) 28 (3–237)
DMARD adminstration history (%) 73.7
Value at the start of MTX admistration: median (minimum–maximum)
MTX methotrexate, DAS28-CRP Disease Activity Score-28 joints–C-reactive
protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor, Scr serum
creatinine, RA rheumatoid arthritis, DMARD disease-modifying
antirheumatic drug
Table 2 Comparisons between disease control status during 6–12 months and cumulative dose of MTX, improved DAS28 area, and
index R for 0–3 and 0–6 months after the start of MTX administration between the good and poor control groups
Disease control status during 6–12 months
p-valueGood (n = 7) Poor (n = 14)
0–3 months after the start of MTX administration
Cumulative dose of MTX (mg) 96.0 (94.0–116.0) 118.0 (100.0–124.0) 0.322
Improved DAS28 area 25.4 (24.5–26.1) 23.4 (22.6–24.5) 0.004
Index R (1/mg) 0.25 (0.22–0.27) 0.20 (0.19–0.24) 0.079
0–6 months after the start of MTX administration
Cumulative dose of MTX (mg) 192.0 (166.0–212.0) 214.0 (196.0–220.0) 0.287
Improved DAS28 area 51.0 (49.7–52.2) 47.6 (45.1–48.4) 0.001
Index R (1/mg) 0.26 (0.24–0.30) 0.22 (0.21–0.24) 0.025
median (25–75th percentile)
MTX methotrexate, DAS28 Disease Activity Score-28 joints
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Discussion
As there are large interindividual differences in the
response to MTX treatment, we performed a prelim-
inary study on predicting better MTX efficacy in
Japanese patients with RA by investigating the rela-
tionship between treatment response and disease
control status, along with genetic polymorphisms for
MTX-related transporters/enzymes.
The good control group during 0–3 months and 0–6
months after the start of MTX administration showed a
significantly greater improved DAS28 area than the poor
control group (p = 0.004 for 0–3 months, 0.001 for 0–6
months). This result suggests that decreasing the DAS28
score aggressively during the early period of MTX admin-
istration contributes to better disease control and subse-
quent prognosis. Although the therapeutic effect of MTX
is thought to depend on the dose, the cumulative MTX
dose for 0–3 months and 0–6 months did not differ sig-
nificantly difference between the good and poor control
groups (p = 0.322 and 0.287, respectively). Therefore, indi-
vidual differences in treatment response are related to the
difference in the improved DAS28 area. Index R for 0–6
months was significantly greater in the good control group
than in the poor control group (p = 0.025), and there was
a nonsignificant tendency for index R to be greater in the
good control group for 0–3 months (p = 0.079). Therefore,
it appears necessary to tailor the optimal MTX dosage
regimen to each patient because the treatment response
differs among individuals.
Several groups have reported the factors predicting the
response to MTX treatment, which focused on drug dis-
position including SNPs in genes coding for folate path-
way enzymes and MTX transport into and out of cells in
patients with RA in relation to MTX efficacy and
toxicity [25–32]. Recently, for example, Kung et al. have
reported that RFC1 80G > A was associated with MTX
efficacy, but not toxicity [25]. Moya et al. reported that
two FPGS SNPs (rs10987742 and rs10106) were associ-
ated with treatment response and that ABCB1 SNPs
(rs868755, rs10280623, rs 1858923) were associated with
toxicity [26]. Ghodke-Puranik et al. found that SNPs in
MTHFR and RFC1 were associated with MTX efficacy
and SNPs in GGH, SHMT1, and TS with MTX-related
adverse events [27]. The results of Świerkot et al. showed
that MTHFR 677CC, GGH 401TT, and CT genotypes
were associated with a reduction in the number of MTX-
related adverse events [28]. Our results of comparisons
between index R for 0–6 months after starting MTX
administration and RFC1 80 G >A, FPGS 1994 G > A,
GGH −401 C > T, MTHFR 1298 A > C, and TYMS 3′-
UTR (−6/+6) did not show statistically significant differ-
ences or clear correlations among them. For this reason,
we cannot rule out a type II error in our study, i.e., that
the sample was too small to detect significant differences,
because RFC1 80G >A genotypes may be slightly corre-
lated with index R (p = 0.112), although no SNPs were.
The lack of a significant difference in the cumulative dose
of MTX between the good and poor control groups, but a
significant difference in the improved DAS28 area and/or
index R between them, suggests that these SNPs may con-
tribute to better disease control status at 6–12 months. It
is necessary to study this in a larger patient population in-
cluding single-gene polymorphisms and other factors as-
sociated with treatment response.
This study had several limitations. First, the dis-
ease control evaluation period was 6–12 months
after the commencement of MTX administration.
RA is a chronic disease, however, and it has been re-
ported that patients with RA continue receiving
MTX significantly longer than other DMARDs, with
60–70 % of them administered MTX for as long as
5.0–7.5 years [34]. This needs to be observed over
longer-term follow-up. Second, we defined the dis-
ease control status as “good” when the MTX dose
was fixed and patients had clinically stable, well-
controlled symptoms, i.e., no dose change was neces-
sary during the study period, and/or the number of
days patients had a DAS28 score >2 was fewer than
once for 6–12 months after the start of MTX ad-
ministration. These criteria for disease control status
would be difficult to apply in clinical practice. In
previous studies using the DAS as an index, im-
provement from baseline to 3 or 6 months was ob-
served [30, 35–38]. In addition, in one study responders
were defined as patients with a DAS28 ≤ 3.2 and nonre-
sponders as those with a DAS28 > 2.8 [35]; in another
studies, responders were patients with a DAS <2.4 (good
clinical response) and nonresponders were those with a
Table 3 Comparisons between index R for 0–6 months after
the start of MTX administration and RFC1, FPGS1994,
GGH452, MTHFR1298, and TYMS 3'-UTR genotypes
Genotype n Index R p-value
RFC1 80 G/G 6 0.22 (0.21–0.23) 0.112
A allele 15 0.24 (0.22–0.30)
FPGS 1994 G allele 17 0.23 (0.21–0.29) 0.517
A/A 4 0.24 (0.23–0.28)
GGH 452 C/C 11 0.23 (0.22–0.29) 0.973
T allele 10 0.23 (0.22–0.26)
MTHFR 1298 A allele 19 0.23 (0.22–0.28) 0.267
C/C 2 0.27 (0.23–0.31)
TYMS 3'-UTR −6/–6 8 0.23 (0.22–0.23) 0.301
+6 allele 13 0.25 (0.22–0.30)
median (25–75th percentile)
RFC1 reduced folate carrier 1, FPGS folypolyglutamate synthetase, GGH
gammaglutamyl hydrolase enzyme, MTHFR methylenetetrahydrofolate
reductase, TYMS thymidylate synthase
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DAS >2.4 based on the European League Against
Rheumatism (EULAR) response criteria [30, 36–38]. Our
definition of maintaining a DAS28-CRP ≤2.0 continuously
for 6–12 months is stricter. Therefore, it should be con-
firmed whether this would be appropriate in clinical prac-
tice. Furthermore, the present results should be compared
with the results of EULAR improvement criteria, the
change in DAS28 from baseline with MTX administration,
and with ACR20, 50, and 70, along with other treatment
response criteria used in previous studies to determine
whether they are equivalent. Third, we did not evaluate
whether disease control could be achieved with lower
doses of MTX in the good control group, or whether it
could be achieved with higher doses in the poor control
group, because this was a pragmatic observational study.
Further study will be needed to confirm this possibility.
Fourth, we excluded patients with adverse drug reactions
to MTX, because we focused only on a method for pre-
dicting the efficacy of MTX treatment of RA in this study.
The clinical application of this “aggressive” RA treatment
will need to consider the balance between MTX efficacy
and safety. Further study is therefore needed to investigate
the dose of MTX in aggressive RA treatment including
patients with adverse drug reactions to MTX and to deter-
mine which patients should not receive aggressive treat-
ment since they are likely to have adverse reactions. Fifth,
the individual differences in treatment response are
dependent on susceptibility to treatment or MTX
pharmacokinetics, and there are some reports that MTX
polyglutamation concentration in red blood cells may be
correlated with efficacy in adult patients with RA [29, 39–
41], although that concentration was not measured in this
study and the correlation was not investigated. The rela-
tionship between treatment effect and MTX polyglutama-
tion concentration in red blood cells should therefore be
clarified. Finally, the sample size was too small and sensi-
tivity analysis to confirm index R was not performed in
this study because it was a retrospective cohort design,
and it will therefore be necessary to undertake a prospect-
ive study in a larger patient population in the future, in-
cluding sensitivity analysis and the SNPs related to MTX
treatment response studied here.
Conclusion
This study suggested that aggressive RA treatment with
MTX administration from the early period is needed to
obtain a good response after 6 months, although SNPs
for MTX-related transporters/enzymes to predict a better
treatment response to MTX were not identified. Further
study in a larger sample is planned.
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